<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036656</url>
  </required_header>
  <id_info>
    <org_study_id>SYHA136201901/PRO-I</org_study_id>
    <nct_id>NCT04036656</nct_id>
  </id_info>
  <brief_title>Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers</brief_title>
  <official_title>Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Ascending Trial of SYHA 136 Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial used single-center, randomized, double-blind, placebo-controlled, single-dose
      ascending study.

      The trial planned to enroll fifty-six healthy volunteers. The subjects were allocated to
      eight dose groups, including 0.5 mg (3+1), 1 mg (3+1), 2.5 mg (6+2), 5 mg (6+2), 10 mg (6+2),
      20 mg (6+2), 35 mg(6+2) and 50 mg (6+2). Each dose group was allocated test drugs and
      placebos according to the proportion of subjects in the brackets mentioned above.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From Screening period to 12 Days Post dose</time_frame>
    <description>Number of participants that experience Adverse Events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>From Screening period to 12 Days Post dose</time_frame>
    <description>Number of participants that experience Serious Adverse Events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinically significant laboratory assessment abnormalities</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>Number of participants with clinically significant laboratory assessment abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinically significant 12-lead electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinically significant physical examination abnormalities</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>Number of participants with clinically significant physical examination abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the concentration-time curve from time zero to time of the Last Measurable Concentration (AUC0-tlast)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Area Under the concentration-time curve from time zero to time of the Last Measurable Concentration (AUC0-tlast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to infinity (AUCinf)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Area under the concentration-time curve from time 0 to infinity (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Time to reach maximum observed concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Terminal elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CL/F)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Apparent total body clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Apparent volume of distribution (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of SYHA136 excreted in urine (Aeu)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Amount of SYHA136 excreted in urine (Aeu)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLr)</measure>
    <time_frame>Up to 72 hours Post dose</time_frame>
    <description>PK Assessment - Renal clearance (CLr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated Partial Thromboplastin Time(aPTT)</measure>
    <time_frame>Up to 48 hours Post dose</time_frame>
    <description>PD Assessment-Activated Partial Thromboplastin Time(aPTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen(Fbg)</measure>
    <time_frame>Up to 48 hours Post dose</time_frame>
    <description>PD Assessment-Fibrinogen(Fbg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin Time(TT)</measure>
    <time_frame>Up to 48 hours Post dose</time_frame>
    <description>PD Assessment-Thrombin Time(TT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio(INR)</measure>
    <time_frame>Up to 48 hours Post dose</time_frame>
    <description>PD Assessment-International Normalized Ratio(INR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-coagulation Factor Xa assays(AXA)</measure>
    <time_frame>Up to 48 hours Post dose</time_frame>
    <description>PD Assessment-Anti-coagulation Factor Xa assays(AXA)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of SYHA136 1 mg or Placebo matching SYHA136 1 mg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of SYHA136 5 mg or Placebo matching SYHA136 5 mg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of SYHA136 10 mg or Placebo matching SYHA136 10 mg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of SYHA136 20 mg or Placebo matching SYHA136 20 mg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of SYHA136 35 mg or Placebo matching SYHA136 35 mg under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of SYHA136 50 mg or Placebo matching SYHA136 50 mg under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA136 0.5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA136 1 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA136 2.5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA136 5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA136 10 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA136 20 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA136 35 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA136 50 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching SYHA136 0.5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching SYHA136 1 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching SYHA136 2.5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching SYHA136 5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching SYHA136 10 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching SYHA136 20 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching SYHA136 35 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching SYHA136 50 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. When subject signs the informed contest, 18≤ age ≤ 40, Male or female;

          2. Body weight: male ≥50 kg, female ≥45 kg. Body mass index (BMI) of 19.0 to 26.0 kg/m²,
             inclusive;

          3. Subject's with normal or or abnormity without clinical significance judged by the
             investigator by physical examination, vital signs, electrocardiogram, blood routine,
             blood biochemistry, coagulation tests, fecal occult blood, urine routine, serological
             tests and other important indicators;

          4. All subjects who adopt effective non-hormonal contraceptive measures (such as condoms,
             intrauterine devices without drugs, etc.) from the signing of informed consent to
             three months after the end of the study;

          5. Subjects who voluntarily signed the informed consent and are able to cooperate to
             complete the test according to the protocal.

        Exclusion Criteria:

          1. Allergic history to more than one drug or other serious allergic rhistory;

          2. Serious diseases of the central nervous system, cardiovascular system, digestive
             system, respiratory system, urinary system, blood system, metabolic disorders or other
             diseases (such as history of psychosis, malignant tumors, etc.)In the past or now,
             which were not suitable for clinical trials.

          3. History of abnormal bleeding or coagulation disorders (e.g. prone to bruising, gum
             bleeding, prolonged bleeding after tooth extraction, joint hemorrhage, menorrhagia,
             postpartum hemorrhage, vitamin K deficiency, haemorrhagic diseases caused by acquired
             coagulation factor antibodies, trauma, wound or post-operative bleeding, etc.);

          4. History of severe head trauma in 2 years;

          5. Severe gastrointestinal diseases occurred within three months before signing informed
             consent, which affected drug absorption;

          6. Have a disease which Haemorrhage could cause serious consequences, such as peptic
             ulcer;

          7. Had undergone surgery within six months before signing the informed consent; planned
             to undergo surgery (including cosmetic surgery, dental surgery and oral surgery)
             within two weeks after the end of the trial; or planned to take part in vigorous
             exercise (including physical contact exercise or collision exercise) during the trial;

          8. Bleed or donated more than 400 mL within three months before signing informed consent,
             or planned to donate blood during the study or within one month after the end of the
             trial;

          9. Have taken any prescription drugs, nonpreserip drugs, biological products, traditional
             Chinese medicines, herbal medicines, vitamin dietary supplements and health products
             within four weeks before signing the informed consent or use oral long-acting
             contraceptives or implanted long-acting contraceptives;

         10. Subjects participating in other clinical trials and taking trial products, or
             participated in any other clinical trials of drugs within three months before signing
             the informed consent;

         11. History of drugs or drug abuse or alcoholics or drug abuse screening shows positive
             response;

         12. current or past alcoholics (drinking more than 14 standard units per week, 1 Standard
             unit containing 14g alcohol, such as 360 mL beer or 40% spirits or 150 mL wines with
             45 mL alcohol), or alcohol breath test positive;

         13. Smokers: The average daily smoking volume was more than 5 cigarettes within six months
             before signing the informed consent;

         14. Habitually consume excessive caffeine-containing beverages or foods, or foods that may
             affect drug metabolism within four weeks before signing informed consent. Such as:
             coffee (no more than 1100 mL per day), tea (no more than 2200 mL per day), cola (no
             more than 2200 mL per day), functional drinks (no more than 1100 mL per day),
             chocolate (no more than 510 g per day);

         15. Positive with serum immunological test for HBsAg, Anti-HCV, Anti-HIV or Anti-TP;

         16. QTc interval≥450 ms, electrocardiogram abnormality with clinical significance, or
             prolonged history of QTc interval;

         17. Abnormal results of chest X-ray (posterior and anterior) with clinical significance;

         18. Female subjects: positive pregnancy tests or pregnant or breast-feeding or planning to
             conceive, who plan to conceive within three months from the signing of informed
             consent to the end of the study; male subjects: whose partners plan to conceive or
             plan to donate sperm within three months from the signing of informed consent to the
             end of the study;

         19. Not suitable for this trial according to the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

